138 related articles for article (PubMed ID: 34906858)
1. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities.
Liang JW; Li WQ; Nian QY; Xie SH; Yang L; Meng FH
Bioorg Chem; 2022 Feb; 119():105547. PubMed ID: 34906858
[TBL] [Abstract][Full Text] [Related]
2. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Han Y; Xiao W; Wang Z; Shi W; Mao Y; Yu J; Xia G; Liu Y
Eur J Med Chem; 2019 Sep; 178():352-364. PubMed ID: 31200237
[TBL] [Abstract][Full Text] [Related]
4. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
[TBL] [Abstract][Full Text] [Related]
5. JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6.
Ji J; Qin J; Wang X; Lv M; Hou X; Jing A; Zhou J; Zuo L; Liu W; Feng J; Qian Q; Liu Y; Wang X; Liu B
Anticancer Agents Med Chem; 2024; 24(6):400-411. PubMed ID: 38192142
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
[No Abstract] [Full Text] [Related]
9. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
11. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
12. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
[TBL] [Abstract][Full Text] [Related]
14. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
[TBL] [Abstract][Full Text] [Related]
15. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies.
Elsayed HE; Ebrahim HY; Haggag EG; Kamal AM; El Sayed KA
Bioorg Med Chem; 2017 Dec; 25(24):6297-6312. PubMed ID: 29066046
[TBL] [Abstract][Full Text] [Related]
16. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Xu Z; Liu Y; Song B; Ren B; Xu X; Lin R; Zhu X; Chen C; Yang S; Zhu Y; Jiang W; Li W; Xia Y; Hu L; Chen S; Chan CC; Li J; Zhang X; Yang L; Tian X; Ding CZ
Bioorg Med Chem Lett; 2024 Jul; 107():129769. PubMed ID: 38670537
[TBL] [Abstract][Full Text] [Related]
17. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
Guan H; Du Y; Han W; Shen J; Li Q
Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
[TBL] [Abstract][Full Text] [Related]
18. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
19. A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.
Tadesse S; Zhu G; Mekonnen LB; Lenjisa JL; Yu M; Brown MP; Wang S
Future Med Chem; 2017 Sep; 9(13):1495-1506. PubMed ID: 28795589
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
